BRAF and carcinoma: In a previous work we found that a pair of site-specific cAMP analogs (8-PIP-cAMP and 8-HA-cAMP), which, when used in combination, selectively activate PKA I, had a potent antiproliferative effect on two BRAF-positive carcinoma cell lines (ARO and NPA), but not on the BRAF-negative WRO cells [19].